HIV-1 protease inhibitors in development

Expert Opinion on Investigational Drugs

Volumn 11, Issue 3, 2002, Pages 387-395

  Rusconi, Stefano ^a   La Seta Catamancio, Simona ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Antiretrovirals; Clinical efficacy; Drug resistance; HIV 1; Pharmacokinetic; Protease inhibitors

Indexed keywords

AMPRENAVIR; ATAZANAVIR; CYTOCHROME P450; DARUNAVIR; DIDANOSINE; DPC 681; DPC 684; GLUCOSE; INDINAVIR; LIPID; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MOZENAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; TIPRANAVIR; TMC 126; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS RESISTANCE; DIARRHEA; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME INHIBITION; FOOD DRUG INTERACTION; GLUCOSE METABOLISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; LIPID METABOLISM; LIPODYSTROPHY; NAUSEA AND VOMITING; PATIENT CARE; PHYSICIAN; REVIEW; VIRUS REPLICATION; ANTIBIOTIC RESISTANCE; DRUG COMBINATION; DRUG EFFECT; ENZYMOLOGY;

DRUG DESIGN; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS;

EID: 0036193453     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.11.3.387     Document Type: Review

References (70)

1. Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy
2. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection
3. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial
4. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy
5. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT)
6. Nevirapine resistance mutations of human immunodeficiency virus Type 1 selected during therapy
7. Loss of antiviral effect owing to zidovudine and lamivudine double resistance in HIV-1 infected patients in an ongoing open label trial
8. Rational design of peptide-based HIV proteinase inhibitors
9. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans
10. L-735,524: An orally bioavailable human immunodeficiency virus Type 1 protease inhibitor
11. Preformulation studies of a novel HIV protease inhibitor, AG1343
12. Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme
13. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine and zalcitabine
14. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimiter or less
15. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
16. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease
17. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy
18. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy
19. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy
20. HIV population dynamics in vivo: Implications for genetic variations, pathogenesis, and therapy
21. Preventing HIV-1 drug resistance
22. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
23. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus Type 1 protease inhibitor
24. Human immunodeficiency virus Type 1 protease genotypes and in vitro protease inhibitors susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment
25. Constrained evolution of human immunodeficiency virus Type 1 protease during sequential therapy with two distinct protease inhibitors
26. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic meutations
27. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed
28. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society-USA panel
29. Phenotypic drug susceptibility testing predicts long-term virologic suppression beter than treatment history in patients with human immunodeficiency virus infection
30. Antagonism between human immunodeficiency virus Type 1 protease inhibitors indinavir and saquinavir in vitro
31. Ritonavir and saquinavir combination therapy for treatment of HIV
32. Efficacy and safety of twice daily first-line ritonavir/indinavir plus double nucleoside cobination therapy in HIV-infected individuals
33. A Phase II study on ritonavir/nelfinavir combination therapy: 48-week data
34. Pharmacokinetic (PK) drug-interaction between amprenavir (APV) and ritonavir (RTV) in HIV-seronegative subjects after multiple oral dosing
35. The SPICE study: 48-week activity of combinations of saquinavir soft gelatin and nelfinavir with and without nucleoside analogues. Study of protease inhibitor combinations in Europe
36. Co-administration of indinavir (IDV) 1200 mg with nelfinavir (NFV) 1250 mg in a twice daily regimen: Preliminary safety PK activity
37. Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1
38. Virological and clinical implications of resistance to HIV-1 protease inhibitors
39. Resistance to human immunodeficiency virus Type 1 protease inhibitors
40. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538)
41. Selection and analysis of human immunodeficiency virus Type 1 variants with increased resistance to ABT-538, a novel protease inhibitor
42. Cross-resistance analysis of human immunodeficiency virus Type 1 variants individually selected for resistance to five different protease inhibitors
43. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
44. Incidence of HIV-1 resistance and cross-resistance to protease inhibitors after indinavir failure: Impact of subsequent ritonavir/saquinavir combination therapy
45. Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor
46. In vitro combination of PNU-140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolates
47. Pharmacokinetics (PK) interaction between the HIV protease inhibitors tipranavir and ritonavir
48. Multiple-dose, safety, tolerance, and pharmacokinetics of the protease inhibitor PNU-140690 in healthy volunteers
49. Safety and efficacy of PNU-140690, a new non-peptidic HIV protease inhibitor, and genotypic changes in patients in a Phase II study
50. The safety, efficacy and viral dynamics analysis of tipranavir, a new-generation protease inhibitor, in a Phase II study in antiretroviral-Naive HIV-1-infected patients
51. Susceptibility to PNU-140690 (tipranavir) of human immunodeficiency virus Type 1 isolates derived from patients with multidrug resistance to other protease inhibitors
52. Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples
53. Site-directed mutagenesis and in vitro drug selection studies have failed to reveal a consistent genotypic resistance pattern for tipranavir
54. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents
55. Safety and antiviral efficacy of a once-daily HIV-1 protease inhibitor BMS-232632: 24 week result from a Phase II clinical trial 40th Interscience Conference on Antimicrobial Agents and Agents and Chemotherapy
56. In vitro resistance profile of the human immunodeficiency virus Type 1 protease inhibitor BMS-232632
57. BMS-232632 sensitivity of a panel of HIV-1 clinical isolates resistant to one or more approved protease inhibitors
58. Genotypic and phenotypic characterization of human immunodeficiency virus Type 1 variants isolated from patients treated with the protease inhibitor nelfinavir
59. A mutation in human immunodeficiency virus Type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir
60. A mutation in human immunodeficiency virus Type 1 protease at position 88, located outside the active site, confers resistance to the hydroxyethylurea inhibitor SC-55389A
61. Estimate of the frequency of human immunodeficiency virus Type 1 protease inhibitor resistance within unselected virus populations in vitro
62. Effects of a novel HIV-1 protease inhibitor (PI), DMP450, on the pharmacokinetics (PK) of indinavir (IDV) and saquinavir (SQV)
63. Preliminary profile of the antiviral activity, metabolic effects and safety of DMP-450, a novel cyclic urea protease inhibitor
64. Effects of a novel HIV-1 protease inhibitor (PI), DMP450, on cardiac tracing, serum lipids and glucose tolerance, as compared to indinavir
65. Molecular basis of HIV-1 protease drug drug resistance: Structural analysis of mutant proteases complexed with cyclic urea inhibitors
66. DPC 681 and DPC 684: Potent, selective inhibitors of human immunodeficiency virus protease active against clinically relevant mutant variants
67. DPC 681 and DPC 684: Resistance and cross-resistance profiles of second generation HIV protease inhibitors
68. DPC 681 and DPC 684: Selective inhibitors of the viral protease active against resistant variants of HIV
69. A femtomolar HIV-1 protease inhibitor with subnanomolar activity against multidrug resistant HIV-1 strains